利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.03 秒)

    CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING
    3.
    发明申请
    CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING 有权
    用于限制组织治疗中的过度炎症反应的细胞疗法

    公开(公告)号：US20110178502A1

    公开(公告)日：2011-07-21

    申请号：US13031431

    申请日：2011-02-21

    申请人： Mark C. Poznansky ,  Nicolas A.F. Chronos

    发明人： Mark C. Poznansky ,  Nicolas A.F. Chronos

    IPC分类号： A61M5/142 ,  A61K35/28 ,  A61K9/00 ,  A61P29/00 ,  A61P17/02 ,  A61M5/00

    CPC分类号： A61L31/005 ,  A61K35/17 ,  A61L15/40 ,  A61L27/3804 ,  A61L27/3839

    摘要： Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

    摘要翻译： B细胞系的细胞包括前B细胞，前B细胞，前B细胞，未成熟B细胞和一些成熟B细胞，和/或T细胞谱系细胞，和/或T细胞谱系的细胞，特别是那些具有辅助或调节 功能，最优选自体接受者，可以移植到受损组织中以增强损伤后的恢复。 在优选的实施方案中，细胞是基于出现在损伤后几天的损伤部位的细胞，例如巨噬细胞，淋巴细胞，其加速对受伤部位的清理和修复并减轻过度炎症反应， 大概是通过抑制炎性细胞如嗜中性粒细胞和由此而迅速释放的信号。

    Cell therapy for limiting overzealous inflammatory reactions in tissue healing
    4.
    发明授权
    Cell therapy for limiting overzealous inflammatory reactions in tissue healing 有权
    细胞疗法限制组织愈合过程中的过度炎症反应

    公开(公告)号：US09220813B2

    公开(公告)日：2015-12-29

    申请号：US13031431

    申请日：2011-02-21

    申请人： Mark C. Poznansky ,  Nicolas A. F. Chronos

    发明人： Mark C. Poznansky ,  Nicolas A. F. Chronos

    IPC分类号： C12N5/0781 ,  A61L31/00 ,  A61K35/17 ,  A61L15/40 ,  A61L27/38

    CPC分类号： A61L31/005 ,  A61K35/17 ,  A61L15/40 ,  A61L27/3804 ,  A61L27/3839

    摘要： Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

    摘要翻译： B细胞系的细胞包括前B细胞，前B细胞，前B细胞，未成熟B细胞和一些成熟B细胞，和/或T细胞谱系细胞，和/或T细胞谱系的细胞，特别是那些具有辅助或调节 功能，最优选自体接受者，可以移植到受损组织中以增强损伤后的恢复。 在优选的实施方案中，细胞是基于出现在损伤后几天的损伤部位的细胞，例如巨噬细胞，淋巴细胞，其加速对受伤部位的清理和修复并减轻过度炎症反应， 大概是通过抑制炎性细胞如嗜中性粒细胞和由此而迅速释放的信号。

    Fugetactic proteins, compositions and methods of use
    5.
    发明授权
    Fugetactic proteins, compositions and methods of use 失效
    蛋白质组合物，组合物和使用方法

    公开(公告)号：US07745578B2

    公开(公告)日：2010-06-29

    申请号：US10563726

    申请日：2004-07-07

    申请人： Mark C. Poznansky ,  Dahlia Doughty

    发明人： Mark C. Poznansky ,  Dahlia Doughty

    IPC分类号： C07K7/00 ,  C07K14/00 ,  A61K38/00

    CPC分类号： A61K38/1709 ,  A61K35/26 ,  A61K38/17 ,  A61K47/646 ,  C07K14/47 ,  G01N33/5029 ,  G01N33/505

    摘要： This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to promote migratory cell movement away from specific sites in a subject. Specific sites include sites of inflammation, infection, an autoimmune reaction, a tumor and a transplanted organ or tissue.

    摘要翻译： 本发明涉及调节具有迁移能力的细胞运动的组合物和方法。 更具体地，本发明涉及用于促进来自受试者中特定部位的细胞的迁移运动，fugetaxis的组合物和方法。 前述内容尤其适用于治疗特征在于需要促进迁移性细胞移动远离受试者的特定部位的病症。 特定部位包括炎症，感染，自身免疫反应，肿瘤和移植的器官或组织的部位。

    Purposeful movement of human migratory cells away from an agent source
    9.
    发明授权
    Purposeful movement of human migratory cells away from an agent source 有权
    人类迁徙细胞有目的地移动远离代理来源

    公开(公告)号：US07775469B2

    公开(公告)日：2010-08-17

    申请号：US11407477

    申请日：2006-04-20

    申请人： Mark C. Poznansky ,  Andrew D. Luster ,  David T. Scadden

    发明人： Mark C. Poznansky ,  Andrew D. Luster ,  David T. Scadden

    IPC分类号： A61K39/00 ,  A61K45/00

    CPC分类号： G01N33/5029 ,  A61K38/00 ,  C07K14/521 ,  C07K14/8114 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5044 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5058 ,  G01N33/5064 ,  G01N33/5088

    摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.

    摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮或间质来源的细胞运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 更具体地，特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源的运动或排斥。 其他部位包括肿瘤部位，病原体感染部位和生殖细胞承载部位。